Page 5 - Cell Development News Today

In an update to the company's online configurator, Tesla has now stopped taking new reservations for the Cybertruck. The move comes on the heels of Elon Musk announcing the futuristic truck is sold out until 2027.

Elon Musk has called for an end to the war against plastic straws. Given he is the founder of Tesla, a company perhaps doing the most to clean up our environment, this was a bit of a head scratcher. However, Musk's words point to a larger critique of society.

XALT Energy, LLC and the ReCell Center, the US Department of Energy’s Vehicle Technologies Office’s (DOE/VTO) battery recycling center (earlier post), are working to close a technology gap between the world’s increasing use of lithium-ion batteries and the need for advanced, in-process and end-of-life battery recycling options. XALT Energy, a...

Cellectis Provides Business Update and Reports Financial Results for First Quarter 2021 Enrollment ongoing in three Cellectis-sponsored Phase 1 dose-escalation clinical studies BALLI-01 in r/r B-ALL patients, AMELI-01 in r/r AML patients and MELANI-01 in r/r MM patients in 15 US clinical centers Five partnered allogeneic CAR-T product candidates in clinical development through our collaborations with Allogene and Servier: UCART19/ALLO-501 and ALLO-501A in r/r NHL, ALLO-715 and ALLO-605 in r/r M...

Date Time Researchers Reveal How Critical Part of Lung Forms at Cellular Level Researchers from Children’s Hospital of Philadelphia (CHOP) have determined what happens at a cellular level as the lung alveolus forms and allows newborns to breathe air. Understanding this process gives researchers a better sense of how to develop therapies and potentially regenerate this critical tissue in the event of injury. The findings were published online today by the journal Science. The lung develops dur...

Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2020 Financial Results March 04, 2021 16:42 ET | Source: Cellectis Inc. Cellectis Inc. New York, New York, UNITED STATES Enrollment ongoing in 3 Cellectis-sponsored Phase 1 dose-escalation trials BALLI-01 in r/r B-ALL patients, AMELI-01 in r/r AML patients and MELANI-01 in r/r MM patients in 7 leading US clinical centers Preliminary results from our Phase 1 BALLI-01 clinical stud...

Study demonstrates intricate relationship between Prpf19 and Exoc7 in inherited ataxias Spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph Disease (MJD), describes the most common form of dominantly inherited ataxia in many populations worldwide, including Hong Kong and mainland China. SCA3 or MJD patients often present problems with gait and balance, blurred vision, and speech difficulties. The symptoms are progressive, and patients may eventually decline into a bed-ridden stat...

Work has potential implications for new therapies to treat cancer and neurodegenerative disorders A team of Case Western Reserve University researchers has found a way to measure key characteristics of proteins that bind to RNA in cells-a discovery that could improve our understanding of how gene function is disturbed in cancer, neurodegenerative disorders or infections. RNA-short for ribonucleic acid-carries genetic instructions within the body. RNA-binding proteins play an important role in t...

Researchers from Queen Mary University of London, have identified a protein that may represent a novel therapeutic target for the treatment of pancreatic cancer.

EGR1 protein acts as a master regulator of inflammation in macrophages, study suggests Scientists at The Wistar Institute discovered that Early Growth Response 1 (EGR1), a protein that turns on and off specific genes during blood cell development, inhibits expression of pro-inflammatory genes in macrophages. As part of their function to protect the body against pathogens, macrophages play a major role in initiation, maintenance, and resolution of inflammation. The discovery expands the understa...